A chronic myeloid leukemia present with an unusual relapse in central nervous system: A case report
Blast cell in CSF examination. Key Clinical MessageExtramedullary involvement of the central nervous system (CNS) in Chronic Myeloid Leukemia (CML) is an uncommon relapse. In this case, we present a unique instance of a 43-year-old male diagnosed with CML experiencing a CNS blast crisis. (Source: Clinical Case Reports)
Source: Clinical Case Reports - March 27, 2024 Category: General Medicine Authors: Mais Musleh, Qossay Alhussien Tags: CASE REPORT Source Type: research

Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring
ConclusionThe study highlights the link between imatinib ’s pharmacokinetics and elevated CK levels, indicating a possible correlation between specific metabolites and improved treatment response. Individualized monitoring of CK levels and imatinib pharmacokinetics could enhance care for CML patients. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - March 27, 2024 Category: Drugs & Pharmacology Source Type: research

Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
Leukemia, Published online: 26 March 2024; doi:10.1038/s41375-024-02229-3Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? (Source: Leukemia)
Source: Leukemia - March 26, 2024 Category: Hematology Authors: Hagop Kantarjian Susan Branford Massimo Breccia Jorge Cortes Fadi G. Haddad Andreas Hochhaus Timothy Hughes Ghayas C. Issa Elias Jabbour Franck E. Nicolini Koji Sasaki Francois Xavier-Mahon Source Type: research

A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements
Blood Cancer Journal, Published online: 26 March 2024; doi:10.1038/s41408-024-01025-7A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 26, 2024 Category: Hematology Authors: Massimiliano Bonifacio Luigi Scaffidi Maria Cristina Miggiano Davide Facchinelli Luca Tosoni Sara Pezone Davide Griguolo Giulia Ciotti Marco Danini Andrea Bernardelli Rita Bresciani Monica Cavraro Lara Crosera Elena De March Michele Dell ’Eva Laura Doro Source Type: research

A case report of atypical chronic myeloid leukemia with complete hematological and major molecular response to Venetoclax/Azacitidine treatment
Atypical Chronic Myeloid Leukemia (aCML), a myeloproliferative neoplasm with poor prognosis, was reclassified as aCML by the ICC classification, and as MDS/MPN with neutrophilia by the WHO 2022 classification. Due to the heterogeneity of its clinical features and the lack of unique biomarkers, as well as limited treatment options, aCML currently lacks a standardized treatment protocol. In this case report, we reviewed a young man diagnosed with aCML who achieved complete clinical and hematologic remission subsequent to receiving a therapeutic regimen combining Venetoclax and Azacitidine. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 25, 2024 Category: Cancer & Oncology Source Type: research

The role of molecular or cytogenetic response as a favorable prognostic factor before hematopoietic stem cell transplantation for chronic myeloid leukemia
The discovery of tyrosine kinase inhibitors (TKIs) in the late 1990s revolutionized the treatment of patients with chronic myeloid leukemia (CML)1,2. Following the emergence of new TKIs, more recent studies have shown a life expectancy similar to that of the general population, making it possible to discontinue medication to reach the new milestone of treatment-free remission3,4. However, resistance to imatinib can occur in 10-15% of patients on first-line treatment and in approximately 10% of those on second-generation inhibitors5. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 22, 2024 Category: Hematology Authors: Giuliana Rosendo de Oliveira Medeiros, Vaneuza Ara újo Moreira Funke, Alberto Cardoso Martins Lima, Ana Lúcia Vieira Mion, Isabela Menezes, Daniela Carinhanha Setubal, Caroline Bonamin dos Santos Sola, Gláucia Tagliari, Rafael Marchesini, Samir Kanaan Source Type: research

Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib
Clin Lymphoma Myeloma Leuk. 2024 Feb 29:S2152-2650(24)00092-2. doi: 10.1016/j.clml.2024.02.014. Online ahead of print.NO ABSTRACTPMID:38503634 | DOI:10.1016/j.clml.2024.02.014 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 19, 2024 Category: Cancer & Oncology Authors: Fadi G Haddad Cedric Nasnas Koji Sasaki Shilpa Paul Ghayas C Issa Caitlin Rausch Elias Jabbour Hagop Kantarjian Source Type: research

Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib
Clin Lymphoma Myeloma Leuk. 2024 Feb 29:S2152-2650(24)00092-2. doi: 10.1016/j.clml.2024.02.014. Online ahead of print.NO ABSTRACTPMID:38503634 | DOI:10.1016/j.clml.2024.02.014 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 19, 2024 Category: Cancer & Oncology Authors: Fadi G Haddad Cedric Nasnas Koji Sasaki Shilpa Paul Ghayas C Issa Caitlin Rausch Elias Jabbour Hagop Kantarjian Source Type: research

Imatinib treatment and longitudinal growth in pediatric patients with chronic myeloid leukemia: Influence of demographic, pharmacological, and genetic factors in the German CML-PAED cohort
This study examines demographic, pharmacological, and genetic factors associated with impaired longitudinal growth in a uniform pediatric cohort treated with imatinib. We analyzed 94 pediatric patients with chronic myeloid leukemia (CML) diagnosed in the chronic phase and treated with imatinib for >12 months who participated in the Germany-wide CML-PAEDII study between February 2006 and February 2021. During imatinib treatment, significant height reduction occurred, with medians of -0.35 standard deviation score (SDS) at 12 months and -0.76 SDS at 24 months. Cumulative height SDS change (Δheight SDS) showed a more pron...
Source: Haematologica - March 18, 2024 Category: Hematology Authors: Sophie Stiehler Stephanie Sembill Oliver Schleicher Michaela Marx Manfred Rauh Manuela Krumbholz Axel Karow Meinolf Suttorp Joachim Woelfle Carlo Maj Markus Metzler Source Type: research

Imatinib treatment and longitudinal growth in pediatric patients with chronic myeloid leukemia: Influence of demographic, pharmacological, and genetic factors in the German CML-PAED cohort
This study examines demographic, pharmacological, and genetic factors associated with impaired longitudinal growth in a uniform pediatric cohort treated with imatinib. We analyzed 94 pediatric patients with chronic myeloid leukemia (CML) diagnosed in the chronic phase and treated with imatinib for >12 months who participated in the Germany-wide CML-PAEDII study between February 2006 and February 2021. During imatinib treatment, significant height reduction occurred, with medians of -0.35 standard deviation score (SDS) at 12 months and -0.76 SDS at 24 months. Cumulative height SDS change (Δheight SDS) showed a more pron...
Source: Haematologica - March 18, 2024 Category: Hematology Authors: Sophie Stiehler Stephanie Sembill Oliver Schleicher Michaela Marx Manfred Rauh Manuela Krumbholz Axel Karow Meinolf Suttorp Joachim Woelfle Carlo Maj Markus Metzler Source Type: research

Imatinib treatment and longitudinal growth in pediatric patients with chronic myeloid leukemia: Influence of demographic, pharmacological, and genetic factors in the German CML-PAED cohort
This study examines demographic, pharmacological, and genetic factors associated with impaired longitudinal growth in a uniform pediatric cohort treated with imatinib. We analyzed 94 pediatric patients with chronic myeloid leukemia (CML) diagnosed in the chronic phase and treated with imatinib for >12 months who participated in the Germany-wide CML-PAEDII study between February 2006 and February 2021. During imatinib treatment, significant height reduction occurred, with medians of -0.35 standard deviation score (SDS) at 12 months and -0.76 SDS at 24 months. Cumulative height SDS change (Δheight SDS) showed a more pron...
Source: Haematologica - March 18, 2024 Category: Hematology Authors: Sophie Stiehler Stephanie Sembill Oliver Schleicher Michaela Marx Manfred Rauh Manuela Krumbholz Axel Karow Meinolf Suttorp Joachim Woelfle Carlo Maj Markus Metzler Source Type: research

GSE261822 Investigating Immune Escape of Chronic Myeloid Leukemia in Blast Crisis by Comparing T cells from miR-142 KO BCR-ABL versus miR-142 WT BCR-ABL mice
Series Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThis SuperSeries is composed of the SubSeries listed below. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - March 18, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research

The first case of six-way complex translocation of t(4;7;9;22;8;14) in a patient with chronic myeloid leukemia
AbstractIn chronic myeloid leukemia (CML), patients exhibit the t(9;22)(q34.1;q11.2) translocation, resulting in the formation of a Philadelphia chromosome (Ph). However, a subset of CML patients display variant complex translocations, characterized by three-way, four-way, and five-way translocations, which have been occasionally associated with a poor prognosis. This case report presents the first case of a t(9;22) variant six-way complex translocation in CML. The R banding chromosome karyotyping technique was used to obtain preliminary karyotyping results, and the multi-probe FISH technique was used to assist in the veri...
Source: Journal of Hematopathology - March 16, 2024 Category: Pathology Source Type: research

Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors
In conclusion, novel therapeutic perspectives are emerging for CML, holding the potential for substantial advancements in disease treatment.PMID:38488824 | DOI:10.1080/14656566.2024.2331778 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - March 15, 2024 Category: Drugs & Pharmacology Authors: Alessandro Costa Emilia Scalzulli Ida Carmosino Claudia Ielo Maria Laura Bisegna Maurizio Martelli Massimo Breccia Source Type: research

Drug-induced chylothorax as a rare pleural complication in dasatinib therapy for chronic myeloid leukaemia
J R Coll Physicians Edinb. 2024 Mar 14:14782715241237577. doi: 10.1177/14782715241237577. Online ahead of print.ABSTRACTChylothorax is a lymphatic chylous pleural effusion typically associated with traumatic (iatrogenic, non-iatrogenic) and non-traumatic (infections, malignancy, lymphatic disorders) aetiologies. Drug-induced chylothorax is uncommon and mostly reported in association with BCR-ABL tyrosine kinase inhibitor therapy.PMID:38486345 | DOI:10.1177/14782715241237577 (Source: Journal of the Royal College of Physicians of Edinburgh)
Source: Journal of the Royal College of Physicians of Edinburgh - March 15, 2024 Category: General Medicine Authors: Isaac Ks Ng Mamta Ruparel Esther Hl Chan Kay Leong Khoo Source Type: research